When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Jan 3

PMID 34975756

Citations 8

Authors

Kaleen N Hayes

Ulrike Baschant

Barbara Hauser

Andrea M Burden

Elizabeth M Winter

Affiliations

Soon will be listed here.

Abstract

Glucocorticoid-induced osteoporosis (GIOP) leads to fractures in up to 40% of patients with chronic glucocorticoid (GC) therapy when left untreated. GCs rapidly increase fracture risk, and thus many patients with anticipated chronic GC exposures should start anti-osteoporosis pharmacotherapy to prevent fractures. In addition to low awareness of the need for anti-osteoporosis therapy among clinicians treating patients with GCs, a major barrier to prevention of fractures from GIOP is a lack of clear guideline recommendations on when to start and stop anti-osteoporosis treatment in patients with GC use. The aim of this narrative review is to summarize current evidence and provide considerations for the duration of anti-osteoporosis treatment in patients taking GCs based on pre-clinical, clinical, epidemiologic, and pharmacologic evidence. We review the pathophysiology of GIOP, outline current guideline recommendations on initiating and stopping anti-osteoporosis therapy for GIOP, and present considerations for the duration of anti-osteoporosis treatment based on existing evidence. In each section, we illustrate major points through a patient case example. Finally, we conclude with proposed areas for future research and emerging areas of interest related to GIOP clinical management.

Citing Articles

The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34).

Yee C, Meliadis C, Kaya S, Chang W, Alliston T Front Endocrinol (Lausanne). 2024; 15:1342938.

PMID: 39092287 PMC: 11291448. DOI: 10.3389/fendo.2024.1342938.

Effects of Dual-Release Hydrocortisone on Bone Metabolism in Primary and Secondary Adrenal Insufficiency: A 6-Year Study.

Hasenmajer V, Ferrari D, De Alcubierre D, Sada V, Puliani G, Bonaventura I J Endocr Soc. 2023; 8(1):bvad151.

PMID: 38090230 PMC: 10714896. DOI: 10.1210/jendso/bvad151.

Galangin mitigates glucocorticoid-induced osteoporosis by activating autophagy of BMSCs via triggering the PKA/CREB signaling pathway.

Zeng C, Wang S, Gu H, Chen F, Wang Z, Li J Acta Biochim Biophys Sin (Shanghai). 2023; 55(8):1275-1287.

PMID: 37365870 PMC: 10448057. DOI: 10.3724/abbs.2023063.

Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?.

Pofi R, Caratti G, Ray D, Tomlinson J Endocr Rev. 2023; 44(6):975-1011.

PMID: 37253115 PMC: 10638606. DOI: 10.1210/endrev/bnad016.

A bibliometric and visualization analysis of glucocorticoid-induced osteoporosis research from 2012 to 2021.

Jiang B, Feng C, Li C, Tu C, Li Z Front Endocrinol (Lausanne). 2022; 13:961471.

PMID: 35992120 PMC: 9388768. DOI: 10.3389/fendo.2022.961471.

References

Langdahl B, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S . Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone. 2018; 116:58-66. DOI: 10.1016/j.bone.2018.07.013. View

Reid D, Devogelaer J, Saag K, Roux C, Lau C, Reginster J . Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373(9671):1253-63. DOI: 10.1016/S0140-6736(09)60250-6. View

Shi X, Blair H, Yang X, McDonald J, Cao X . Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem. 2000; 76(3):518-27. DOI: 10.1002/(sici)1097-4644(20000301)76:3<518::aid-jcb18>3.0.co;2-m. View

Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F . Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2013; 73(5):854-60. DOI: 10.1136/annrheumdis-2012-202958. View

Amiche M, Abtahi S, Driessen J, Vestergaard P, de Vries F, Cadarette S . Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos. 2018; 13(1):30. PMC: 5857556. DOI: 10.1007/s11657-018-0424-x. View

Kanis J, Johansson H, Oden A, Johnell O, De Laet C, Melton Iii L . A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 19(6):893-9. DOI: 10.1359/JBMR.040134. View

Hauser B, Alonso N, Riches P . Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups. J Clin Med. 2021; 10(7). PMC: 8037129. DOI: 10.3390/jcm10071403. View

Solomon D, Katz J, Jacobs J, La Tourette A, Coblyn J . Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum. 2002; 46(12):3136-42. DOI: 10.1002/art.10613. View

Adachi J, Saag K, Delmas P, Liberman U, Emkey R, Seeman E . Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44(1):202-11. DOI: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. View

10.

Yao W, Cheng Z, Busse C, Pham A, Nakamura M, Lane N . Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008; 58(6):1674-86. PMC: 3892702. DOI: 10.1002/art.23454. View

11.

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2001; 39(12):1383-9. DOI: 10.1093/rheumatology/39.12.1383. View

12.

Canalis E, Mazziotti G, Giustina A, Bilezikian J . Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18(10):1319-28. DOI: 10.1007/s00198-007-0394-0. View

13.

Balasubramanian A, Wade S, Adler R, Saag K, Pannacciulli N, Curtis J . Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. J Bone Miner Res. 2018; 33(10):1881-1888. DOI: 10.1002/jbmr.3523. View

14.

Minisola S, Cipriani C, Della Grotta G, Colangelo L, Occhiuto M, Biondi P . Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019; 11:1759720X19877994. PMC: 6778993. DOI: 10.1177/1759720X19877994. View

15.

Naunton M, Peterson G, Jones G, Griffin G, Bleasel M . Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol. 2004; 31(3):550-6. View

16.

Menant J, Weber F, Lo J, Sturnieks D, Close J, Sachdev P . Strength measures are better than muscle mass measures in predicting health-related outcomes in older people: time to abandon the term sarcopenia?. Osteoporos Int. 2016; 28(1):59-70. DOI: 10.1007/s00198-016-3691-7. View

17.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

18.

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

19.

van Staa T, Leufkens H, Cooper C . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10):777-87. DOI: 10.1007/s001980200108. View

20.

Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017; 357:j1415. PMC: 6284230. DOI: 10.1136/bmj.j1415. View